Molecular Diagnostics Market (Technology: PCR & Real-time PCR, Hybridization, Microarray, Transcription-mediated Amplification, Next Generation Sequencing, and Others; Application: Infectious Diseases [Virology and Bacteriology], Oncology, Blood Screening, Microbiology, Genetic Testing, and Women’s Health; and End-user: Hospitals, Diagnostics Laboratories, Blood Banks, Academics & Research, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Molecular Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. End-user Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Molecular Diagnostics Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Future Market Outlook

    5.2. Key Industry Events

    5.3. Porter’s Five Force Analysis

    5.4. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)

6. Global Molecular Diagnostics Market Analysis and Forecast, by End-user

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by End-user, 2017–2030

        6.3.1. PCR & Real-time PCR

        6.3.2. Hybridization

        6.3.3. Microarray

        6.3.4. Transcription-mediated Amplification

        6.3.5. Next-Generation Sequencing

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by End-user

7. Global Molecular Diagnostics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2030

        7.3.1. Infectious Diseases

            7.3.1.1. Virology

            7.3.1.2. Bacteriology

        7.3.2. Oncology

        7.3.3. Blood Screening

        7.3.4. Microbiology

        7.3.5. Genetic Testing

        7.3.6. Women’s Health

    7.4. Market Attractiveness Analysis, by Application

8. Global Molecular Diagnostics Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017–2030

        8.3.1. Hospitals

        8.3.2. Diagnostics Laboratories

        8.3.3. Blood Banks

        8.3.4. Academics & Research

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global Molecular Diagnostics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Molecular Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by End-user, 2017–2030

        10.2.1. PCR & Real-time PCR

        10.2.2. Hybridization

        10.2.3. Microarray

        10.2.4. Transcription-mediated Amplification

        10.2.5. Next-Generation Sequencing

        10.2.6. Others

    10.3. Market Value Forecast, by Application, 2017–2030

        10.3.1. Infectious Diseases

            10.3.1.1. Virology

            10.3.1.2. Bacteriology

        10.3.2. Oncology

        10.3.3. Blood Screening

        10.3.4. Microbiology

        10.3.5. Genetic Testing

        10.3.6. Women’s Health

    10.4. Market Value Forecast, by End-user, 2017–2030

        10.4.1. Hospitals

        10.4.2. Diagnostics Laboratories

        10.4.3. Blood Banks

        10.4.4. Academics & Research

        10.4.5. Others

    10.5. Market Value Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By End-user

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Molecular Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by End-user, 2017–2030

        11.2.1. PCR & Real-time PCR

        11.2.2. Hybridization

        11.2.3. Microarray

        11.2.4. Transcription-mediated Amplification

        11.2.5. Next-Generation Sequencing

        11.2.6. Others

    11.3. Market Value Forecast, by Application, 2017–2030

        11.3.1. Infectious Diseases

            11.3.1.1. Virology

            11.3.1.2. Bacteriology

        11.3.2. Oncology

        11.3.3. Blood Screening

        11.3.4. Microbiology

        11.3.5. Genetic Testing

        11.3.6. Women’s Health

    11.4. Market Value Forecast, by End-user, 2017–2030

        11.4.1. Hospitals

        11.4.2. Diagnostics Laboratories

        11.4.3. Blood Banks

        11.4.4. Academics & Research

        11.4.5. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By End-user

        11.6.2. By Application

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Molecular Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by End-user, 2017–2030

        12.2.1. PCR & Real-time PCR

        12.2.2. Hybridization

        12.2.3. Microarray

        12.2.4. Transcription-mediated Amplification

        12.2.5. Next-Generation Sequencing

        12.2.6. Others

    12.3. Market Value Forecast, by Application, 2017–2030

        12.3.1. Infectious Diseases

            12.3.1.1. Virology

            12.3.1.2. Bacteriology

        12.3.2. Oncology

        12.3.3. Blood Screening

        12.3.4. Microbiology

        12.3.5. Genetic Testing

        12.3.6. Women’s Health

    12.4. Market Value Forecast, by End-user, 2017–2030

        12.4.1. Hospitals

        12.4.2. Diagnostics Laboratories

        12.4.3. Blood Banks

        12.4.4. Academics & Research

        12.4.5. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By End-user

        12.6.2. By Application

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Molecular Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by End-user, 2017–2030

        13.2.1. PCR & Real-time PCR

        13.2.2. Hybridization

        13.2.3. Microarray

        13.2.4. Transcription-mediated Amplification

        13.2.5. Next-Generation Sequencing

        13.2.6. Others

    13.3. Market Value Forecast, by Application, 2017–2030

        13.3.1. Infectious Diseases

            13.3.1.1. Virology

            13.3.1.2. Bacteriology

        13.3.2. Oncology

        13.3.3. Blood Screening

        13.3.4. Microbiology

        13.3.5. Genetic Testing

        13.3.6. Women’s Health

    13.4. Market Value Forecast, by End-user, 2017–2030

        13.4.1. Hospitals

        13.4.2. Diagnostics Laboratories

        13.4.3. Blood Banks

        13.4.4. Academics & Research

        13.4.5. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By End-user

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Molecular Diagnostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by End-user, 2017–2030

        14.2.1. PCR & Real-time PCR

        14.2.2. Hybridization

        14.2.3. Microarray

        14.2.4. Transcription-mediated Amplification

        14.2.5. Next-Generation Sequencing

        14.2.6. Others

    14.3. Market Value Forecast, by Application, 2017–2030

        14.3.1. Infectious Diseases

            14.3.1.1. Virology

            14.3.1.2. Bacteriology

        14.3.2. Oncology

        14.3.3. Blood Screening

        14.3.4. Microbiology

        14.3.5. Genetic Testing

        14.3.6. Women’s Health

    14.4. Market Value Forecast, by End-user, 2017–2030

        14.4.1. Hospitals

        14.4.2. Diagnostics Laboratories

        14.4.3. Blood Banks

        14.4.4. Academics & Research

        14.4.5. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By End-user

        14.6.2. By Application

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2020

    15.3. Company Profiles

        15.3.1. Abbott Laboratories

            15.3.1.1. Company Overview

            15.3.1.2. Business Overview

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Becton, Dickinson and Company

            15.3.2.1. Company Overview

            15.3.2.2. Business Overview

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Bio-Rad Laboratories, Inc.

            15.3.3.1. Company Overview

            15.3.3.2. Business Overview

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. BioMérieux SA

            15.3.4.1. Company Overview

            15.3.4.2. Business Overview

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Danaher Corporation

            15.3.5.1. Company Overview

            15.3.5.2. Business Overview

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. F. Hoffmann-La Roche Ltd.

            15.3.6.1. Company Overview

            15.3.6.2. Business Overview

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. QIAGEN N.V.

            15.3.7.1. Company Overview

            15.3.7.2. Business Overview

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Siemens AG

            15.3.8.1. Company Overview

            15.3.8.2. Business Overview

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Thermo Fisher Scientific Inc.

            15.3.9.1. Company Overview

            15.3.9.2. Business Overview

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview